Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lessened by GAM Holding AG

GAM Holding AG cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,057 shares of the pharmaceutical company’s stock after selling 234 shares during the period. GAM Holding AG’s holdings in Vertex Pharmaceuticals were worth $4,050,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Northwest Investment Counselors LLC acquired a new position in shares of Vertex Pharmaceuticals in the third quarter worth $25,000. Highline Wealth Partners LLC purchased a new position in Vertex Pharmaceuticals in the third quarter valued at about $27,000. Dunhill Financial LLC increased its position in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the last quarter. Brown Lisle Cummings Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $30,000. Finally, Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at about $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research report on Monday, December 16th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. UBS Group upped their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Barclays raised their target price on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Finally, Piper Sandler decreased their price target on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Ten investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $505.57.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the completion of the sale, the executive vice president now directly owns 64,021 shares of the company’s stock, valued at $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $459.00 on Tuesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm’s 50-day simple moving average is $435.69 and its 200 day simple moving average is $460.99. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.